Biller Scott 4
4 · AGIOS PHARMACEUTICALS INC · Filed Apr 9, 2019
Insider Transaction Report
Form 4
Biller Scott
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common stock
2019-04-05$39.76/sh+3,000$119,280→ 29,511 total - Exercise/Conversion
Stock option (right to buy)
2019-04-05−3,000→ 39,648 totalExercise: $39.76Exp: 2026-02-15→ Common stock (3,000 underlying) - Sale
Common stock
2019-04-05$67.61/sh−2,401$162,332→ 27,110 total - Sale
Common stock
2019-04-05$68.12/sh−599$40,804→ 26,511 total
Holdings
- 53,059(indirect: See footnote)
Common stock
Footnotes (6)
- [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $67.00 to $67.99. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $68.00 to $68.27. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]Shares held by a trust, of which the reporting person is trustee and beneficiary.
- [F6]This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.